Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets
Shots:
- Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration
- Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up to five neuromuscular targets. Following exercising of an option, Codiak will be responsible for research and preclinical development through IND preparation while Sarepta will lead clinical development and commercial activities
- The collaboration will leverage Codiak’s exosome engineering capabilities with Sarepta’s expertise in precision genetic medicine to develop next-generation therapeutics targeting the needs of patients with neuromuscular diseases
Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: STAT